Sanara MedTech(SMTI) GlobeNewswire·2025-01-21 21:10Core Article Summary - Sanara MedTech Inc has entered into an exclusive license and distribution agreement with Biomimetic Innovations Ltd (BMI) for OsStic, a synthetic injectable structural bio-adhesive bone void filler, and related technologies [1][2] - The agreement includes an initial cash investment of €4.0 million by Sanara, with an additional €4.0 million contingent upon achieving development, clinical, and regulatory milestones [1] - OsStic has received Breakthrough Device Designation from the FDA, targeting over 100,000 periarticular fractures annually in the US [1][3] Agreement Details - Sanara acquires exclusive US marketing, sales, and distribution rights for OsStic and a hardware-agnostic adjunctive internal fixation technology [2] - The initial term of the agreement is five years, with options for successive two-year renewals at Sanara's discretion [2] Product and Market Potential - OsStic is designed to enhance fracture repair by optimizing fluidic dispersion, interdigitating with bone structure, and adhering firmly to bone surfaces, offering superior structural integrity compared to traditional materials [4] - The product is expected to complement Sanara's existing surgical portfolio and is anticipated to launch in the US market by Q1 2027 [4] Strategic and Financial Implications - The partnership leverages Sanara's existing commercial infrastructure and call points, enhancing its surgical product offerings [1] - The investment aligns with Sanara's strategy to improve clinical outcomes and reduce healthcare expenditures in the surgical and wound care markets [1][6] Industry and Company Background - Biomimetic Innovations Ltd, an affiliate of PBC Biomed, specializes in medical device development and commercialization, with a track record of bringing innovative technologies to market [5] - Sanara MedTech Inc focuses on transformative technologies in surgical, chronic wound, and skincare markets, with a robust product portfolio and pipeline [6]